Physician profile
Josh Littell
NPI 1386322147
$3,051.67
in general payments reported to CMS, 2019-2025
21 companies · $1,291 in 2025
The $1,291 reported for 2025 was more than what 90% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $234 · 2024: $1,526 · 2025: $1,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,012 · Education: $39.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,011.87 |
| Education | $39.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $471.70 | 2023-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $385.84 | 2023-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $324.87 | 2023-2025 | |
| Fresenius USA Marketing, INC. | $302.79 | 2024-2025 | Velphoro, Velphoro |
| Opko Pharmaceuticals, LLC | $234.55 | 2023-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $208.23 | 2023-2025 | |
| Vifor Pharma, INC. | $172.68 | 2024-2025 | Veltassa |
| Ani Pharmaceuticals, INC. | $144.14 | 2024-2025 | Purified Cortrophin Gel |
| Amgen INC. | $141.31 | 2024-2025 | Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.92 | 2023-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $95.04 | 2024-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $79.06 | 2024 | Lupkynis |
| Scpharmaceuticals INC. | $75.77 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $74.70 | 2024 | |
| Ardelyx, INC. | $63.46 | 2025 | Ibsrela |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $58.71 | 2024-2025 | Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $32.04 | 2025 | |
| Glaxosmithkline, LLC. | $29.97 | 2024 | Benlysta |
| Genzyme Corporation | $22.32 | 2024 | |
| Cormedix INC. | $19.52 | 2025 | Defencath |
| Alexion Pharmaceuticals, INC. | $19.05 | 2025 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josh Littell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.